Workflow
DBV Technologies(DBVT) - 2025 Q2 - Quarterly Report

Part I – Financial Information Item 1. Financial Statements This section presents the unaudited condensed consolidated financial statements, including the statements of financial position, operations and comprehensive loss, cash flows, and changes in shareholders' equity, along with detailed notes explaining significant accounting policies, clinical program updates, financing events, and other financial details Condensed Consolidated Statements of Financial Position (Unaudited) Condensed Consolidated Statements of Financial Position (in thousands) | Metric | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | | :-------------------------------- | :----------------------------- | :------------------------------- | | Assets | | | | Cash and cash equivalents | $103,207 | $32,456 | | Total current assets | $121,241 | $44,388 | | Total non-current assets | $22,188 | $21,271 | | Total Assets | $143,429 | $65,658 | | Liabilities | | | | Total current liabilities | $49,425 | $31,136 | | Total non-current liabilities | $7,780 | $7,135 | | Total Liabilities | $57,205 | $38,271 | | Shareholders' Equity | | | | Total Shareholders' equity | $86,224 | $27,387 | | Total Liabilities and Shareholder's equity | $143,429 | $65,658 | - Total Assets increased significantly from $65.7 million at December 31, 2024, to $143.4 million at June 30, 2025, primarily driven by a substantial increase in cash and cash equivalents16 - Total Shareholders' Equity rose from $27.4 million at December 31, 2024, to $86.2 million at June 30, 2025, reflecting recent financing activities16 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands) | Metric (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Operating income | $1,465 | $1,161 | $2,217 | $2,568 | | Research and development expenses | $(33,693) | $(25,374) | $(55,176) | $(46,777) | | Sales and marketing expenses | $(419) | $(986) | $(681) | $(1,744) | | General and administrative expenses | $(8,463) | $(8,643) | $(14,089) | $(16,447) | | Total Operating expenses | $(42,575) | $(35,003) | $(69,946) | $(64,968) | | Loss from operations | $(41,111) | $(33,842) | $(67,728) | $(62,400) | | Financial income (expense) | $(648) | $726 | $(1,109) | $1,986 | | Net loss | $(41,875) | $(33,116) | $(68,954) | $(60,461) | | Basic/diluted Net loss per share | $(0.31) | $(0.34) | $(0.58) | $(0.63) | - Net loss increased to $(41.9) million for the three months ended June 30, 2025, from $(33.1) million in the prior year, and to $(69.0) million for the six months ended June 30, 2025, from $(60.5) million in the prior year19 - Research and development expenses significantly increased by 33% for the three months and 18% for the six months ended June 30, 2025, reflecting increased clinical trial activities19 Condensed Consolidated Statements of Cash Flows (Unaudited) Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activity (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :----------------------------- | :----------------------------- | | Net cash flow used in operating activities | $(53,573) | $(69,765) | | Net cash flows used in investing activities | $(413) | $(1,441) | | Net cash flows provided by (used in) financing activities | $116,992 | $(95) | | Effect of exchange rate changes on cash and cash equivalents | $7,746 | $(3,853) | | Net (decrease) / increase in cash and cash equivalents | $70,752 | $(75,154) | | Net Cash and cash equivalents at the end of the period | $103,207 | $66,213 | - Net cash provided by financing activities was $117.0 million for the six months ended June 30, 2025, a significant increase from $(95) thousand in the prior year, primarily due to a recent financing operation21181 - Net cash used in operating activities decreased by $16.2 million to $53.6 million for the six months ended June 30, 2025, compared to $69.8 million in the prior year, due to contained costs and extended payment terms21178 Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) Condensed Consolidated Statements of Changes in Shareholders' Equity (in thousands) | Equity Component (in thousands) | Balance at January 1, 2025 | Balance at June 30, 2025 | | :------------------------------ | :------------------------- | :----------------------- | | Ordinary shares (Amount) | $11,651 | $15,393 | | Additional paid-in capital | $315,613 | $391,546 | | Treasury stock | $(1,309) | $(1,238) | | Accumulated deficit | $(286,375) | $(315,136) | | Accumulated other comprehensive income | $905 | $861 | | Accumulated currency translation effect | $(13,097) | $(5,202) | | Total Shareholders' Equity | $27,387 | $86,224 | - Total Shareholders' Equity increased from $27.4 million at January 1, 2025, to $86.2 million at June 30, 2025, primarily due to capital increases from the issuance of ordinary shares and share warrants26101 - The Company's share capital increased from €10,285,886.80 to €13,694,887.20 due to the full subscription and payment of 34,090,004 new ordinary shares101 Notes to the Condensed Consolidated Financial Statements (Unaudited) Note 1: The Company - DBV Technologies S.A. is a clinical-stage biopharmaceutical company developing Viaskin, a novel epicutaneous immunotherapy platform, for food allergies27118 - The financial statements are prepared in accordance with U.S. GAAP and are unaudited, with estimates and assumptions used that may differ from actual results283031 - The Company has incurred operating losses and negative cash flows since inception, and despite recent financing, there is substantial doubt about its ability to continue as a going concern into the second quarter of 20263437164 Note 2: Significant Events and Transactions - For Viaskin Peanut in toddlers (1-3 years), the FDA has agreed to an Accelerated Approval pathway, requiring the COMFORT Toddlers safety study (initiated June 2025) and a confirmatory effectiveness study to be initiated at BLA submission5556657273 - For Viaskin Peanut in children (4-7 years), the COMFORT Children supplemental safety study is no longer required, as VITESSE Phase 3 safety data will suffice for BLA filing, with submission planned for H1 2026, potentially accelerating launch by one year5777120 - The Company completed a financing on April 7, 2025, raising $125.5 million (€116.3 million) in gross proceeds, with potential for up to an additional $181.4 million (€168.2 million) from warrant exercises, contingent on VITESSE Phase 3 results363878163165 Note 3: Cash and Cash Equivalents Cash and Cash Equivalents (in thousands) | Category | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--------- | :----------------------------- | :------------------------------- | | Cash | $29,371 | $32,456 | | Cash equivalents | $73,836 | — | | Total | $103,207 | $32,456 | - Total cash and cash equivalents increased significantly to $103.2 million as of June 30, 2025, from $32.5 million at December 31, 2024, primarily due to the inclusion of $73.8 million in cash equivalents90 Note 4: Other Current Assets Other Current Assets (in thousands) | Category | June 30, 2025 (in thousands) | December 31, 2024 (in thousands) | | :------------------ | :----------------------------- | :------------------------------- | | Research tax credit | $2,378 | $3,980 | | Other tax claims | $10,428 | $4,452 | | Prepaid expenses | $2,343 | $1,541 | | Other receivables | $2,885 | $1,959 | | Total | $18,034 | $11,932 | - Other current assets increased by $6.1 million to $18.0 million at June 30, 2025, mainly due to a significant rise in other tax claims (primarily VAT reimbursement) and prepaid expenses9193 - The research tax credit receivable decreased from $3.98 million to $2.38 million, with $2.2 million estimated for the first six months of 20259192 Note 5: Lease contracts Lease contracts (in thousands) | Lease Liability (in thousands) | June 30, 2025 | December 31, 2024 | | :----------------------------- | :------------ | :---------------- | | Current portion | $998 | $654 | | Long-term lease liabilities | $6,696 | $6,297 | | Total Present value of lease liabilities | $7,695 | $6,951 | | Weighted average remaining lease term (years) | 7.17 | 7.49 | | Weighted average discount rate | 5.13% | 5.02% | - Operating lease expense decreased to $562 thousand for the six months ended June 30, 2025, from $1,255 thousand in the prior year, partly due to a net restructuring impact95 - Cash paid for operating leases decreased significantly to $180 thousand for the six months ended June 30, 2025, from $1,019 thousand in the prior year95 Note 6: Trade Payables and Other Liabilities Trade Payables and Other Liabilities (in thousands) | Liability Category (in thousands) | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :------------ | :---------------- | | Trade payables | $40,792 | $22,032 | | Employee related liabilities | $6,293 | $7,294 | | Tax liabilities | $625 | $188 | | Other debts | $600 | $846 | | Total Other current liabilities | $7,518 | $8,328 | - Trade payables increased by $18.8 million to $40.8 million at June 30, 2025, reflecting increased clinical trials and manufacturing expenditures1696 - Other current liabilities decreased to $7.5 million at June 30, 2025, from $8.3 million at December 31, 2024, mainly due to changes in bonus accruals within employee-related liabilities1697 Note 7: Shareholders' equity - As of June 30, 2025, the share capital is €13,697,370, divided into 136,973,697 ordinary shares with a par value of €0.1098 - The Company's share capital increased from €10,285,886.80 to €13,694,887.20 following the full subscription of 34,090,004 new ordinary shares as part of the March 2025 financing101 - Net income for FY2024 was allocated to retained earnings, resulting in a debit balance of €102.3 million, and the share premium account was cleared, leaving a debit balance of €67.1 million on retained earnings99 Note 8: Share-Based Payments Share-Based Payments | Share-Based Instrument | Balance as of Dec 31, 2024 | Granted | Forfeited | Exercised/Released | Expired | Balance as of June 30, 2025 | | :--------------------- | :------------------------- | :------ | :-------- | :----------------- | :------ | :-------------------------- | | Non-employee warrants (BSA) | 244,693 | — | — | — | (49,185) | 195,508 | | Stock options (SO) | 10,452,903 | 215,000 | (66,100) | — | (128,100) | 10,473,703 | | Restricted stock units (RSUs) | 2,813,366 | 35,000 | (82,850) | (36,192) | — | 2,729,324 | Share-Based Compensation Expense (in thousands) | Expense Category (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research & development | $(543) | $(697) | $(1,124) | $(1,466) | | Sales & marketing | $(19) | $(29) | $(37) | $(61) | | General & administrative | $(683) | $(799) | $(1,786) | $(1,956) | | Total share-based compensation (expense) | $(1,246) | $(1,525) | $(2,947) | $(3,483) | - Total share-based compensation expense decreased to $(1.2) million for the three months and $(2.9) million for the six months ended June 30, 2025, compared to the prior year periods105 Note 9: Contingencies Contingencies (in thousands) | Contingency Type (in thousands) | June 30, 2025 | December 31, 2024 | | :------------------------------ | :------------ | :---------------- | | Current contingencies | $117 | $122 | | Non-current contingencies | $1,084 | $838 | | Total contingencies | $1,201 | $961 | - Total contingencies increased to $1.2 million at June 30, 2025, from $961 thousand at December 31, 2024, driven by increases in pension retirement obligations and other contingencies, along with currency translation effects106 Note 10: Operating income Operating income (in thousands) | Operating Income (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research tax credit | $1,465 | $1,161 | $2,217 | $2,568 | | Total | $1,465 | $1,161 | $2,217 | $2,568 | - Research tax credit increased by $0.3 million for the three months ended June 30, 2025, due to more eligible activities, particularly the launch of the COMFORT Toddlers clinical trial107 - Research tax credit decreased by $0.4 million for the six months ended June 30, 2025, as a greater proportion of clinical studies were conducted in North America, making them ineligible for the French Research tax credit107 Note 11: Operating Expenses Personnel Expenses by Function (in thousands) | Personnel Expenses by Function (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :------------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Research and Development expenses | $5,697 | $5,177 | $10,327 | $10,225 | | Sales & Marketing expenses | $194 | $233 | $350 | $567 | | General & Administrative expenses | $3,908 | $3,413 | $6,904 | $6,650 | | Total personnel expenses | $9,799 | $8,824 | $17,581 | $17,442 | - Total personnel expenses increased for both the three-month and six-month periods ended June 30, 2025, primarily due to recruitments in Q2 2024 and retroactive salary increases in Q2 2025109 - The average number of employees increased to 109 during the six months ended June 30, 2025, from 106 in the prior year, supporting development and quality activities108 Note 12: Commitments - There were no significant changes in other commitments from those disclosed in the Annual Report110 Note 13: Relationships with Related Parties - The Company authorized three new related party transactions as part of the March 27, 2025 financing, including Securities Purchase Agreements with Baker Brothers Advisors LP and BPIfrance Participations SA, and a Registration Rights Agreement with investors111113 Note 14: Loss Per Share Loss Per Share | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Basic/diluted Net loss per share | $(0.31) | $(0.34) | $(0.58) | $(0.63) | | Weighted average shares outstanding | 134,476,503 | 96,170,285 | 118,545,638 | 96,179,388 | Excluded Potential Shares | Excluded Potential Shares | As of June 30, 2025 | As of June 30, 2024 | | :------------------------ | :------------------ | :------------------ | | Non-employee warrants | 195,508 | 244,693 | | Stock options | 10,473,703 | 7,535,091 | | Restricted stock units | 2,729,324 | 2,188,071 | | Prefunded warrants | 127,361,991 | 28,276,331 | - Diluted loss per share is equal to basic loss per share because the Company was in a net loss position, making the effects of potentially dilutive shares anti-dilutive111 Note 15: Events after the Close of the Period - There were no significant events after the close of the period113 Note 16: Reportable segment disclosure - The Company operates and is managed as one operating segment, focusing on the development of the Viaskin Peanut patch114 Reportable segment disclosure (in thousands) | Expense Category (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Clinical studies | $16,258 | $13,056 | $23,060 | $21,229 | | BLA & Regulatory | $2,298 | $1,610 | $3,683 | $3,090 | | Manufacturing & Supply and Quality | $12,786 | $8,507 | $23,380 | $17,403 | | Sales & Marketing | $419 | $986 | $681 | $1,744 | | General & Administrative | $8,463 | $8,643 | $14,089 | $16,447 | | Total expenses | $42,575 | $35,003 | $69,946 | $64,968 | Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations This section provides management's perspective on the Company's financial condition, results of operations, and liquidity, including an overview of its clinical programs, critical accounting policies, and detailed comparisons of financial performance for the three and six months ended June 30, 2025 and 2024 Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on epicutaneous immunotherapy (EPIT) using its Viaskin patch technology, which delivers biologically active compounds through intact skin to target Langerhans cells and activate the immune system with minimal systemic exposure118 - The Company is developing two Viaskin Peanut patch candidates for peanut allergy: one for toddlers aged 1-3 years (original patch, supported by EPITOPE study and COMFORT Toddlers safety study under Accelerated Approval pathway) and another for children aged 4-7 years (modified patch, evaluated in VITESSE Phase 3 study, BLA filing planned for H1 2026)119120121123125 - Regulatory alignment has been achieved with the FDA for the Accelerated Approval pathway for toddlers, and the COMFORT Children supplemental safety study for 4-7 year-olds is no longer required123125120 Critical Accounting Policies and Significant Judgments and Estimates - There have been no new policies or significant changes to the Company's critical accounting policies as disclosed in the Annual Report129 Business Trends and Results of Operations Comparison of the Three Months Ended June 30, 2025 and 2024 Comparison of the Three Months Ended June 30, 2025 and 2024 (in thousands) | Metric (in thousands) | Q2 2025 | Q2 2024 | $ Change | % Change | | :-------------------------------- | :------ | :------ | :------- | :------- | | Operating income | $1,465 | $1,161 | $303 | 26% | | Research and development expenses | $(33,693) | $(25,374) | $(8,319) | 33% | | Sales and marketing expenses | $(419) | $(986) | $567 | (58)% | | General and administrative expenses | $(8,463) | $(8,643) | $180 | (2)% | | Total Operating expenses | $(42,575) | $(35,003) | $(7,572) | 22% | | Financial income (expense) | $(648) | $726 | $(1,374) | (189)% | | Net loss | $(41,875) | $(33,116) | $(8,759) | 26% | - Research and Development expenses increased by $8.3 million (33%) due to the launch of the COMFORT Toddlers study, progress of the VITESSE Phase 3 study, and increased regulatory and production activities134135 - Sales and Marketing expenses decreased by $0.6 million (58%) due to lower activities, reduced sales headcount, and decreased travel expenses137 - Financial income shifted to an expense of $(0.6) million from an income of $0.7 million, primarily due to unfavorable foreign exchange results from the appreciation of EUR vs USD143 Comparison of the Six Months Ended June 30, 2025 and 2024 Comparison of the Six Months Ended June 30, 2025 and 2024 (in thousands) | Metric (in thousands) | H1 2025 | H1 2024 | $ Change | % Change | | :-------------------------------- | :------ | :------ | :------- | :------- | | Operating income | $2,217 | $2,568 | $(351) | (14)% | | Research and development expenses | $(55,176) | $(46,777) | $(8,399) | 18% | | Sales and marketing expenses | $(681) | $(1,744) | $1,063 | (61)% | | General and administrative expenses | $(14,089) | $(16,447) | $2,358 | (14)% | | Total Operating expenses | $(69,946) | $(64,968) | $(4,978) | 8% | | Financial income (expense) | $(1,109) | $1,986 | $(3,095) | (156)% | | Net loss | $(68,954) | $(60,461) | $(8,493) | 14% | - Operating income decreased by $0.4 million (14%) due to a greater proportion of clinical studies being conducted in North America, making them ineligible for the French Research tax credit149 - Research and Development expenses increased by $8.4 million (18%) due to the launch of the COMFORT Toddlers study, progress of the VITESSE Phase 3 study, and regulatory/production activities150151 - General and Administrative expenses decreased by $2.4 million (14%) due to lower external professional services (non-recurring costs, office relocations, trademarks) and reduced depreciation/amortization155156157 Liquidity and Capital Resources Financial Condition - Cash and cash equivalents increased to $103.2 million at June 30, 2025, from $32.5 million at December 31, 2024, following a $125.5 million financing on April 7, 2025162163 - The Company estimates its cash and cash equivalents are sufficient to fund operations into the second quarter of 2026, but there is substantial doubt about its ability to continue as a going concern due to ongoing operating losses164 - The financing includes potential additional gross proceeds of up to $181.4 million from warrant exercises, which could be accelerated by positive VITESSE Phase 3 study results165 Sources of Liquidity and Material Cash Requirements - The 2025 PIPE financing included a share capital increase of €38 million (issuance of ABSA) and an issue of €79 million in PFW-BS-PFW units, with proceeds allocated to working capital, Viaskin Peanut program development, BLA submission, and US launch readiness169181 - The Company's material cash requirements include operating lease obligations for its French headquarters ($6.8 million ending March 2033) and US offices ($1.6 million ending December 2029)170171 - Obligations under CRO agreements for ongoing clinical trials amounted to $272.7 million as of June 30, 2025, an increase from $170.3 million at December 31, 2024, driven by the COMFORT Toddlers and VITESSE studies174175 Summary Statement of Cash Flows Summary Statement of Cash Flows (in thousands) | Cash Flow Activity (in thousands) | H1 2025 | H1 2024 | $ Change | % Change | | :-------------------------------- | :------ | :------ | :------- | :------- | | Net cash flow used in operating activities | $(53,573) | $(69,765) | $16,192 | (23)% | | Net cash flow used in investing activities | $(413) | $(1,441) | $1,027 | (71)% | | Net cash flow provided by (used in) financing activities | $116,992 | $(95) | $117,087 | (123261)% | | Net (decrease) increase in cash and cash equivalents | $70,752 | $(75,154) | $145,906 | (194)% | - Net cash flow used in operating activities decreased by $16.2 million, primarily due to contained costs, extended payment terms, and deferral of R&D and S&M activities178179 - Net cash flow provided by financing activities significantly increased to $117.0 million, driven by the financing operation completed on April 7, 2025181 Off-Balance Sheet Arrangements - The Company has not entered into any off-balance sheet arrangements182 Smaller Reporting Company Status - The Company is a smaller reporting company, allowing it to take advantage of scaled disclosures183 Item 3. Quantitative and Qualitative Disclosures About Market Risk As a smaller reporting company, DBV Technologies is not required to provide quantitative and qualitative disclosures about market risk - The Company is exempt from providing quantitative and qualitative disclosures about market risk due to its status as a smaller reporting company184 Item 4. Controls and Procedures This section details the Company's disclosure controls and procedures, management's assessment of their effectiveness, and any changes in internal control over financial reporting, while also acknowledging the inherent limitations of any control system Disclosure Controls and Procedures - Management, including the CEO and CFO, concluded that the Company's disclosure controls and procedures were effective as of June 30, 2025, providing reasonable assurance for timely and accurate reporting186 Changes in Internal Control Over Financial Reporting - There were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company's internal control during the period187 Limitation on Effectiveness of Controls and Procedures - Management acknowledges that control systems provide only reasonable, not absolute, assurance and are subject to inherent limitations such as faulty judgments, simple errors, circumvention by individuals or collusion, and management override188 Part II – Other Information Item 1. Legal Proceedings The Company is not currently subject to any material legal proceedings, as referenced in the notes to the condensed consolidated financial statements - The Company is not currently subject to any material legal proceedings89190 Item 1A. Risk Factors This section refers to the risk factors detailed in the Annual Report, emphasizing the substantial doubt about the Company's ability to continue as a going concern due to ongoing operating losses and liquidity challenges - As of June 30, 2025, substantial doubt exists about the Company's ability to continue as a going concern due to ongoing operating losses and liquidity challenges192 - The Company's business is subject to various risks that could adversely affect its financial condition, results of operations, and stock trading price192 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Details of unregistered equity securities issued during the six months ended June 30, 2025, including ordinary shares issued upon RSU settlements and shares/warrants from the 2025 PIPE financing, all exempt from Securities Act registration - During the six months ended June 30, 2025, the Company issued unregistered securities, including ordinary shares from RSU settlements to US and non-US employees193200 - The Company also issued 34,090,004 New Shares with ABSA Warrants and 71,005,656 First Pre-Funded Warrants as part of the 2025 PIPE financing on March 27, 2025, completed on April 7, 2025193200 - These transactions were exempt from registration under Section 4(a)(2) or Regulation S of the Securities Act, as they did not involve a public offering193 Item 3. Defaults Upon Senior Securities The Company reported no defaults upon senior securities during the period - There were no defaults upon senior securities195 Item 4. Mine Safety Disclosures Mine safety disclosures are not applicable to the Company - Mine safety disclosures are not applicable to the Company197 Item 5. Other Information No Rule 10b5-1 trading arrangements were adopted, modified, or terminated by the Company's directors and officers during the three months ended June 30, 2025 - None of the Company's directors and officers adopted, modified, or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trade arrangement" during the three months ended June 30, 2025199 Item 6. Exhibits This section lists all exhibits filed as part of the Quarterly Report on Form 10-Q, including by-laws, CEO/CFO certifications, and XBRL documents - The exhibits include by-laws, CEO and CFO certifications (pursuant to Sections 302 and 906 of Sarbanes-Oxley Act), and various XBRL taxonomy documents202